skip to Main Content


Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer’s Patients

Can we develop a reliable blood test to identify both the presence and severity of Alzheimer’s Disease? How does plasma exchange affect the markers of Alzheimer’s disease progression?

Apply now

Recruiting Alzheimer's patients for a plasmapheresis trial

MaxWell Clinic is recruiting a committed cohort of Alzheimer’s patients for a trial to evaluate plasmapheresis and how it may benefit those with Alzheimer’s disease or cognitive impairment.

Plasmapheresis is an FDA-approved procedure for more than 50 indications and it has been shown to improve a range of health measures. A previous trial, called The AMBAR study, was designed to evaluate whether the progression of Alzheimer’s could be stabilized through therapeutic plasma exchange. The results showed a reduced disease progression in patients with mild-to-moderate Alzheimer’s, as well as a reduction in decline in memory, orientation, and judgment. Our trial at MaxWell Clinic will continue to research this life-changing therapy.

What is plasmapharesis or Therapeutic Plasma Exchange?

As you get older, your blood becomes polluted with “rusty” proteins and “sticky” molecules that may adversely affect your brain and body. By “rusty” we mean damaged by oxygen, and by “sticky” we mean damaged in a way to stimulate the immune system and cause inflammation. Since your blood is the river of nourishment for your cells, your cells’ health is influenced by the health of your blood.

Therapeutic Plasma Exchange helps to clean your blood and removes certain harmful substances circulating in your plasma.

This innovative therapy has the potential to slow down the rate of brain and body degeneration.


This trial will be conducted in collaboration with the University of Iowa and FBB BioMed. If successful, this study will allow the creation of a reliable blood test that will allow clinicians to diagnose Alzheimer’s sooner and with better clarity as to its severity. This is the first of several planned studies to review the impact of plasma exchange on eliminating or reducing the presence of these potentially damaging RNA sequences in Alzheimer’s patients.

MaxWell Clinic is a nationwide leader in providing outpatient plasma exchange services to treat autoimmune disease, neurodegenerative disease, and the promotion of healthy longevity.

Participant Benefits

All participants will receive one Plasma Exchange at no cost. Through participation, you will also contribute to the advancement of human knowledge and the development of life-improving therapeutics!

Participant Requirements

This study aims to understand plasmapheresis effects in committed volunteers who are currently in various stages of Alzheimer’s. The treatment and follow-up visits require a totla of 5 visits to MaxWell Clinic over the course of 28 days. Participants will undergo 1 Therapeutic Plasma exchange and then have blood drawn on days 7, 14, 21 and 28. Once the final blood sample is collected on day 28 that marks the completion of the participant’s involvement.
Participants must have good veins and not be afraid of needles.

Find out if you qualify to participate

Have a question about this Clinical Trial?

Please call our Clinical Research Coordinator at 615-370-0091, ext 1172, or schedule a call below.